2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. PDGFR

PDGFR

Platelet-derived growth factor receptor

PDGFR

Related Products

PDF 1.46 MB

PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.

PDGFR Isoform Specific Products:

PDGFR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10372
    PP121
    		Inhibitor 98.67%
    PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2/KDR/Flk-1, Src, PDGFR, respectively.
    PP121
  • HY-13049
    Cediranib maleate
    		Inhibitor 99.95%
    Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, VEGFR2/KDR/Flk-1, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
    Cediranib maleate
  • HY-10202
    Tandutinib
    		Inhibitor 99.48%
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML). Tandutinib has the ability to cross the blood-brain barrier.
    Tandutinib
  • HY-109190
    Seralutinib
    		Inhibitor 99.77%
    Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
    Seralutinib
  • HY-13894
    Tyrphostin AG1296
    		Inhibitor 99.69%
    Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range.
    Tyrphostin AG1296
  • HY-10527
    Telatinib
    		Inhibitor 99.60%
    Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.
    Telatinib
  • HY-W011266
    JNJ-10198409
    		Inhibitor 99.57%
    JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM).
    JNJ-10198409
  • HY-109019
    Vorolanib
    		Inhibitor 99.88%
    Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895).
    Vorolanib
  • HY-10330A
    Toceranib phosphate
    		Inhibitor 98.54%
    Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and VEGFR2/KDR/Flk-1/VEGFR2/KDR/Flk-1, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
    Toceranib phosphate
  • HY-108713
    Famitinib
    		Inhibitor 98.43%
    Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis.
    Famitinib
  • HY-124526
    Chiauranib
    		Inhibitor 99.28%
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.
    Chiauranib
  • HY-10408
    Ki20227
    		Inhibitor 99.17%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
    Ki20227
  • HY-10207
    Dovitinib lactate
    		Inhibitor 99.62%
    Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/Flt-1/2/3 and PDGFRα/β, respectively.
    Dovitinib lactate
  • HY-16265
    JI-101
    		Inhibitor 99.78%
    JI-101 is an orally available multi-kinase inhibitor of VEGFR2/KDR/Flk-1, PDGFRβ and EphB4 with potent anti-cancer activity.
    JI-101
  • HY-15506
    TAK-593
    		Inhibitor 99.62%
    TAK-593 is a potent VEGFR and PDGFR family inhibitor with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDFGRα and PDFGRβ, respectively.
    TAK-593
  • HY-10185
    TG 100572 Hydrochloride
    		Inhibitor 98.96%
    TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572 Hydrochloride
  • HY-10330
    Toceranib
    		Inhibitor
    Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and VEGFR2/KDR/Flk-1/VEGFR2/KDR/Flk-1, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
    Toceranib
  • HY-100315
    Tyrosine kinase-IN-1
    		Inhibitor 99.34%
    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for VEGFR2/KDR/Flk-1, Flt-1, FGFR1 and PDGFRα, respectively.
    Tyrosine kinase-IN-1
  • HY-10987
    ENMD-2076 Tartrate
    		Inhibitor 99.42%
    ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, VEGFR2/KDR/Flk-1/VEGFR2/KDR/Flk-1, Flt4/VEGFR3/Flt-4, FGFR1, FGFR2, Src, PDGFRα, respectively.
    ENMD-2076 Tartrate
  • HY-18622
    PP58
    		Inhibitor 99.75%
    PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values.
    PP58
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
PDGFR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.